Markus Britschgi

The paper identifies two compounds, trifluoperazine and deoxytubercidin, as novel microglial phagocytosis inhibitors using high-throughput screening and in vivo validation.

The paper shows that experimental colitis increases alpha-synuclein accumulation in the gut and brain, linking intestinal inflammation to Parkinson's disease pathology.

This study identifies elevated toxic bile acids in Parkinson's disease patients and links them to gut microbiome dysbiosis and early biliary changes.

The paper identifies early gut biomarkers for Parkinson's disease in mice and humans using a transgenic model and molecular profiling.

The paper reports two new polymorphic structures of alpha-synuclein fibrils solved by cryo-EM, showing distinct structural features and interactions compared to previous structures.

The paper uses 3D multicolor STED microscopy to study subcellular distribution of alpha-synuclein variants in Parkinson’s disease brains, revealing their association with pathology.

The paper uses high-resolution imaging and biophysical methods to show that Lewy pathology in Parkinson's disease consists mainly of a crowded membranous medley of vesicles and dysmorphic organelles, with only a small fraction containing proteinaceous filaments.

The paper reports the cryo-EM structure of alpha-synuclein fibrils, revealing key features relevant to disease mechanisms and therapeutic design.